The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Pharmacology of mTOR Inhibition
Abstract
The quest for effective cancer therapies reveals insight into the regulation and function of the mammalian target of rapamycin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rapamycin and other mTOR antagonists are well-known autophagy inducers that promote clearance of protein aggregates through the inhibition of the mTOR signaling pathway, thereby removing the inhibition upon autophagy [97].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“The mechanism requires the Rag GTPases, which, by binding to Raptor, may promote the colocalization of mTORC1 with its activator, Rheb, in response to amino acid sufficiency (6, 7).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Self-citationPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Self-citationGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
Self-citationJacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Regulation of TORC1 by Rag GTPases in nutrient response
Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P., & Guan, K.-L. (2008) · Nature Cell Biology · doi:10.1038/ncb1753 · Cited by 1,349 · cited 1×
“The mechanism requires the Rag GTPases, which, by binding to Raptor, may promote the colocalization of mTORC1 with its activator, Rheb, in response to amino acid sufficiency (6, 7).”
Background
Cited by
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Regulation of Mammalian Autophagy in Physiology and Pathophysiology
Ravikumar, B., Sarkar, S., Davies, J. E., Futter, M., Garcia-Arencibia, M., Green-Thompson, Z. W., Jimenez-Sanchez, M., Korolchuk, V. I., Lichtenberg, M., Luo, S., et al. (2010) · Physiological Reviews · doi:10.1152/physrev.00030.2009 · Cited by 1,727
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120
Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila Melanogaster
Bjedov, I., Toivonen, J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A., & Partridge, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.010 · Cited by 1,057
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
With TOR, Less Is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging
Kapahi, P., Chen, D., Rogers, A. N., Katewa, S. D., Li, P. W.-L., Thomas, E. L., & Kockel, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.05.001 · Cited by 660
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
Xu, Z., Han, X., Ou, D., Liu, T., Li, Z., Jiang, G., Liu, J., & Zhang, J. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10257-8 · Cited by 612
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
Zhao, J., Zhai, B., Gygi, S. P., & Goldberg, A. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521919112 · Cited by 484
Autophagy activation by rapamycin reduces severity of experimental osteoarthritis
Caramés, B., Hasegawa, A., Taniguchi, N., Miyaki, S., Blanco, F. J., & Lotz, M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200557 · Cited by 455
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
mTOR in aging, metabolism, and cancer
Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 449
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
Kang, S. A., Pacold, M. E., Cervantes, C. L., Lim, D., Lou, H. J., Ottina, K., Gray, N. S., Turk, B. E., Yaffe, M. B., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1236566 · Cited by 431
Self-citationmTOR and cancer: many loops in one pathway
Efeyan, A., & Sabatini, D. M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.10.007 · Cited by 430
Self-citationDin, F. V. N., Valanciute, A., Houde, V. P., Zibrova, D., Green, K. A., Sakamoto, K., Alessi, D. R., & Dunlop, M. G. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.050 · Cited by 418
Cap and cap‐binding proteins in the control of gene expression
Topisirovic, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2011) · WIREs RNA · doi:10.1002/wrna.52 · Cited by 401
Complex Inhibitory Effects of Nitric Oxide on Autophagy
Sarkar, S., Korolchuk, V. I., Renna, M., Imarisio, S., Fleming, A., Williams, A., Garcia-Arencibia, M., Rose, C., Luo, S., Underwood, B. R., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.029 · Cited by 383
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis
Howell, J. J., & Manning, B. D. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.12.003 · Cited by 331
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirovic, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 324
Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Guo, D., Bell, E., Mischel, P., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 323
Engineering the ABA Plant Stress Pathway for Regulation of Induced Proximity
Liang, F.-S., Ho, W. Q., & Crabtree, G. R. (2011) · Science Signaling · doi:10.1126/scisignal.2001449 · Cited by 314
Growing knowledge of the mTOR signaling network
Huang, K., & Fingar, D. C. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.09.011 · Cited by 305
mTOR signaling in cellular and organismal energetics
Albert, V., & Hall, M. N. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.001 · Cited by 304
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
Sparks, C. A., & Guertin, D. A. (2010) · Oncogene · doi:10.1038/onc.2010.139 · Cited by 299
Self-citationTargeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
Blanchet, F. P., Moris, A., Nikolic, D. S., Lehmann, M., Cardinaud, S., Stalder, R., Garcia, E., Dinkins, C., Leuba, F., Wu, L., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.011 · Cited by 295
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
The multifaceted role of mTORC1 in the control of lipid metabolism
Ricoult, S. J. H., & Manning, B. D. (2013) · EMBO reports · doi:10.1038/embor.2013.5 · Cited by 286
Roelants, F. M., Breslow, D. K., Muir, A., Weissman, J. S., & Thorner, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116948108 · Cited by 282
Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., Dang, J., Zhu, S., Yang, H., De Jesus, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0124 · Cited by 275
Jhanwar-Uniyal, M., Wainwright, J. V., Mohan, A. L., Tobias, M. E., Murali, R., Gandhi, C. D., & Schmidt, M. H. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.003 · Cited by 268
Zakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213
mTOR links oncogenic signaling to tumor cell metabolism
Yecies, J. L., & Manning, B. D. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0726-6 · Cited by 183
Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070690 · Cited by 172
Defining essential genes for human pluripotent stem cells by CRISPR–Cas9 screening in haploid cells
Yilmaz, A., Peretz, M., Aharony, A., Sagi, I., & Benvenisty, N. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0088-1 · Cited by 139
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Shibuya, Y., Chang, C. C. Y., Huang, L.-H., Bryleva, E. Y., & Chang, T.-Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2567-14.2014 · Cited by 108
“In addition, when WT and A1 KO microglia were nutrient-starved by incubating in Hanks Balanced Salt Solution (HBSS) for 3 h, or by treating with a potent mTOR inhibitor Torin1 (Guertin and Sabatini, 2009) for 3 h, the mTOR activities were suppressed to very similar levels in both cell types.”
MethodFox, J. H., Connor, T., Chopra, V., Dorsey, K., Kama, J. A., Bleckmann, D., Betschart, C., Hoyer, D., Frentzel, S., DiFiglia, M., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-26 · Cited by 94
“Everolimus, like rapamycin, inhibits the kinase activity of the raptormTOR complex (mTORC1) by binding to the protein FKBP-12, which forms an inhibitory complex with mTOR [12,13].”
BackgroundJobim, P. F. C., Pedroso, T. R., Christoff, R. R., Werenicz, A., Maurmann, N., Reolon, G. K., & Roesler, R. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.10.002 · Cited by 92
Jobim, P. F. C., Pedroso, T. R., Werenicz, A., Christoff, R. R., Maurmann, N., Reolon, G. K., Schröder, N., & Roesler, R. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.004 · Cited by 68
Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis
Franz, D. N., & Weiss, B. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0269-4 · Cited by 58
Coupling between Nutrient Availability and Thyroid Hormone Activation
Lartey, L. J., Werneck-de-Castro, J. P., O-Sullivan, I., Unterman, T. G., & Bianco, A. C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665505 · Cited by 41
“Inhibition of mTOR Pathway Prevents FBS and Insulin-mediated D2 Stimulation—We next used PP242, a selective ATPcompetitive inhibitor of both mTORC1 and mTORC2 (38, 39) to test the involvement of the mTOR signaling pathway in the D2 stimulation by FBS or insulin.”
MethodHuang, K.-C., Gomes, C., Shiga, Y., Belforte, N., VanderWall, K. B., Lavekar, S. S., Fligor, C. M., Harkin, J., Hetzer, S. M., Patil, S. V., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01872-2 · Cited by 19
mTORC2 deficiency alters the metabolic profile of conventional dendritic cells
Watson, A. R., Dai, H., Zheng, Y., Nakano, R., Giannou, A. D., Menk, A. V., Stolz, D. B., Delgoffe, G. M., & Thomson, A. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01451 · Cited by 15
“mTOR is known to function in two discrete complexes: mTOR complex 1 (mTORC1) (5) and mTORC2 (6).”
Background
Metadata
- Authors
- Guertin, D. A., & Sabatini, D. M.
- Venue
- Science Signaling
- Published
- 2009-04-21
- Volume
- 2
- Issue
- 67
- Pages
- pe24-pe24
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2008825756
- Cited by
- 568
- References
- 36
- FWCI
- 26.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.